Target Price | $322.32 |
Price | $293.85 |
Potential | 9.69% |
Number of Estimates | 31 |
31 Analysts have issued a price target Amgen 2026 . The average Amgen target price is $322.32. This is 9.69% higher than the current stock price. The highest price target is $425.25 44.72% , the lowest is $181.80 38.13% . | |
A rating was issued by 40 analysts: 21 Analysts recommend Amgen to buy, 16 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2026 of 9.69% . Most analysts recommend the Amgen stock at Purchase. |
34 Analysts have issued a sales forecast Amgen 2025 . The average Amgen sales estimate is $36.4b . This is 4.28% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $38.0b 8.81% , the lowest is $34.6b 1.04% .
This results in the following potential growth metrics:
2024 | $33.4b | 18.57% |
---|---|---|
2025 | $36.4b | 8.94% |
2026 | $37.0b | 1.71% |
2027 | $38.0b | 2.62% |
2028 | $38.3b | 0.77% |
2029 | $39.6b | 3.45% |
2030 | $41.4b | 4.62% |
2031 | $42.5b | 2.43% |
2032 | $43.2b | 1.65% |
34 Amgen Analysts have issued a net profit forecast 2025. The average Amgen net profit estimate is $11.6b . This is 74.71% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $12.2b 84.52% , the lowest is $10.9b 64.41% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.1b | 39.11% |
---|---|---|
2025 | $11.6b | 182.74% |
2026 | $11.9b | 2.52% |
2027 | $12.3b | 3.72% |
2028 | $12.7b | 2.96% |
2029 | $13.2b | 4.44% |
2030 | $14.2b | 7.22% |
2031 | $14.8b | 4.37% |
2032 | $15.3b | 3.19% |
2024 | 12.24% | 48.64% |
---|---|---|
2025 | 31.76% | 159.55% |
2026 | 32.01% | 0.79% |
2027 | 32.36% | 1.09% |
2028 | 33.06% | 2.16% |
2029 | 33.38% | 0.97% |
2030 | 34.21% | 2.49% |
2031 | 34.86% | 1.90% |
2032 | 35.38% | 1.49% |
34 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is $21.49 . This is 75.72% higher than earnings per share in the financial year 2024. The highest EPS forecast is $22.70 85.61% , the lowest is $20.23 65.41% .
This results in the following potential growth metrics and future valuations:
2024 | $7.56 | 39.47% |
---|---|---|
2025 | $21.49 | 184.26% |
2026 | $22.04 | 2.56% |
2027 | $22.86 | 3.72% |
2028 | $23.53 | 2.93% |
2029 | $24.58 | 4.46% |
2030 | $26.35 | 7.20% |
2031 | $27.50 | 4.36% |
2032 | $28.38 | 3.20% |
Current | 24.03 | 42.78% |
---|---|---|
2025 | 13.67 | 43.11% |
2026 | 13.33 | 2.49% |
2027 | 12.86 | 3.53% |
2028 | 12.49 | 2.88% |
2029 | 11.96 | 4.24% |
2030 | 11.15 | 6.77% |
2031 | 10.68 | 4.22% |
2032 | 10.35 | 3.09% |
Based on analysts' sales estimates for 2025, the Amgen stock is valued at an EV/Sales of 5.67 and an P/S ratio of 4.34 .
This results in the following potential growth metrics and future valuations:
Current | 5.91 | 15.69% |
---|---|---|
2025 | 5.67 | 4.10% |
2026 | 5.57 | 1.68% |
2027 | 5.43 | 2.55% |
2028 | 5.39 | 0.77% |
2029 | 5.21 | 3.33% |
2030 | 4.98 | 4.42% |
2031 | 4.86 | 2.37% |
2032 | 4.78 | 1.62% |
Current | 4.53 | 16.56% |
---|---|---|
2025 | 4.34 | 4.10% |
2026 | 4.27 | 1.68% |
2027 | 4.16 | 2.55% |
2028 | 4.13 | 0.77% |
2029 | 3.99 | 3.33% |
2030 | 3.82 | 4.42% |
2031 | 3.73 | 2.37% |
2032 | 3.67 | 1.62% |
Analyst | Rating | Action | Date |
---|---|---|---|
B of A Securities |
Underperform
➜
Underperform
|
Unchanged | Sep 26 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Aug 25 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 06 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Aug 06 2025 |
Citigroup |
Neutral
➜
Neutral
|
Unchanged | Aug 06 2025 |
B of A Securities |
Underperform
➜
Underperform
|
Unchanged | Jul 23 2025 |
Citigroup |
Neutral
➜
Neutral
|
Unchanged | Jul 22 2025 |
Analyst Rating | Date |
---|---|
Unchanged
B of A Securities:
Underperform
➜
Underperform
|
Sep 26 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Aug 25 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 06 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Aug 06 2025 |
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Aug 06 2025 |
Unchanged
B of A Securities:
Underperform
➜
Underperform
|
Jul 23 2025 |
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Jul 22 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.